Owens & Minor misses Q3 revenue estimates, reaffirms FY guidance

Accendra Health

30/10/2025 20:36

Overview

Owens & Minor misses analysts' expectations for Q3 revenue

However, adjusted EBITDA beats consensus

Company shifts focus to home-based care, with sale of Products & Healthcare Services

Outlook

Company reaffirms 2025 revenue guidance of $2.76 bln to $2.82 bln

Owens & Minor maintains 2025 adjusted EPS guidance of $1.02 to $1.07

Company expects 2025 adjusted EBITDA between $376 mln and $382 mln

Result Drivers

STRATEGIC SHIFT - Owens & Minor's sale of Products & Healthcare Services segment aligns with focus on home-based care, per CEO Edward A. Pesicka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$697.30 mln
$1.13 bln (5 Analysts)
Q3 Net Income
-$150.27 mln
Q3 Adjusted EBITDA
Beat
$92.20 mln
$91.59 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Owens & Minor Inc is $6.50, about 19.7% above its October 29 closing price of $5.22

Press Release: ID:nBw1NGQ9fa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)